This blog explores these novel treatments, their efficacy in specific NSCLC populations, and their potential pathway to US approval.
Emerging NSCLC Treatments: Novel Therapies from Global Markets Awaiting US Approval Read More »
Learn how Eva thrives four years after her ALK-positive lung cancer diagnosis, combining targeted treatments, creativity, and a supportive community to live life to the fullest.
Living with ALK+ Lung Cancer: A 4-Year Journey of Strength Read More »
Julia’s battle with metastatic lung cancer began in July 2016, right in the midst of her wedding preparations. A persistent pressure in the neck and an unusual breathing sound prompted a visit to her primary care physician.
7 Years in Palliative Care: A Journey with Metastatic NSCLC Read More »
A 41-year-old retired firefighter and combat veteran went from stage IV lung cancer to no evidence of disease in just six months, thanks to ALK-targeted therapy and surgery at MD Anderson. Today, he’s back to training for IRONMAN and enjoying life with his family.
From Stage IV Lung Cancer to Cancer-Free: A Remarkable Recovery Read More »
Stage IV lung cancer, brain metastases, PD-L1 positive. Treated with chemotherapy and immunotherapy
Complete Brain and Body Response – Immunotherapy Triumph Read More »
Stage IV lung cancer, brain metastasis, ALK-positive. Treated with immunotherapy, chemotherapy, stereotactic radiosurgery, and alectinib
Remarkable outcomes in Advanced ALK-Postive lung cancer Read More »
